Mauna Kea Technologies enrolls 200+ in new clinical study: 3 things to know

Mauna Kea Technologies has enrolled more than 200 patients in its CONTACT II clinical study.

Advertisement

Here are three things to know:

1. The study focuses on the characterization of pancreatic cysts with needle-based confocal laser endomicroscopy.

2. Mauna Kea Technologies is the creator of Cellvizio, a multidisciplinary confocal laser endomicroscopy platform.

3. Further clinical evidence of the safety and efficacy of with needle-based confocal laser endomicroscopy is expected to strengthen the CLE technology.

More articles on GI/endoscopy:
Healthmark introduces endoscope brush
AGA selects Dr. Nelson Garcia for future leaders program
5 GI physicians in the news

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.